Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Piflufolastat F-18

FDA-approved product (solution, intravenous), marketed as Pylarify, Pylarify Truvu.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Piflufolastat F-18
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Computed tomography
  • Metastatic prostate cancer
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Piflufolastat F-18 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Piflufolastat F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

    NCT03585114 · start 2018-12-11

    Registered record
    Registry ID
    NCT03585114
    Conditions
    Metastatic Prostate Cancer
    Interventions
    [F-18] DCFPyL; PET/CT imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-12-11
    Completion
    2022-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    Intervention[F-18] DCFPyL; PET/CT imaging
    PhasePhase 2
    Registry statusActive not recruiting

  • PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

    NCT03594760 · start 2018-12-01

    Registered record
    Registry ID
    NCT03594760
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFPyL IV injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-12-01
    Completion
    2029-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFPyL IV injection
    PhasePhase 3
    Registry statusRecruiting

  • PSMA-PET Registry for Recurrent Prostate Cancer

    NCT03718260 · start 2018-09-27

    Registered record
    Registry ID
    NCT03718260
    Conditions
    Recurrent Prostate Cancer
    Interventions
    [18F]-DCFPyL or [18F]PSMA-1007 PET/ CT scan (PSMA PET)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-09-27
    Completion
    2026-06-15
    Enrolment
    9,684

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Cancer
    Intervention[18F]-DCFPyL or [18F]PSMA-1007 PET/ CT scan (PSMA PET)
    PhaseNot applicable
    Registry statusCompleted

  • PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life

    NCT03609736 · start 2018-08-10

    Registered record
    Registry ID
    NCT03609736
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFPyL PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-08-10
    Completion
    2019-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFPyL PET/CT
    PhaseNot recorded
    Registry statusUnknown

  • 18F-DCFPyL PET-CT Scan and Prostate Cancer

    NCT03852654 · start 2018-07-22

    Registered record
    Registry ID
    NCT03852654
    Conditions
    Prostate Cancer Adenocarcinoma
    Interventions
    18F-DCFPyL
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2018-07-22
    Completion
    2020-06-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Adenocarcinoma
    Intervention18F-DCFPyL
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

    NCT03253744 · start 2018-07-05

    Registered record
    Registry ID
    NCT03253744
    Conditions
    Prostate Cancer; Prostatic Neoplasm
    Interventions
    18F-DCFPyL; Tumor Irradiation; Prostate + tumor irradiation; Tumor Irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-05
    Completion
    2025-01-30
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Prostatic Neoplasm
    Intervention18F-DCFPyL; Tumor Irradiation; Prostate + tumor irradiation; Tumor Irradiation
    PhasePhase 1
    Registry statusCompleted

  • Prostate Cancer Patient Management With 18F-DCFPyL PET/CT

    NCT03459820 · start 2018-06-22

    Registered record
    Registry ID
    NCT03459820
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFPyL PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Enrolling by invitation
    Start
    2018-06-22
    Completion
    2028-06
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFPyL PET/CT
    PhasePhase 2 / Phase 3
    Registry statusEnrolling by invitation

  • PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

    NCT03392181 · start 2018-06-08

    Registered record
    Registry ID
    NCT03392181
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFPyL
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2018-06-08
    Completion
    2026-06-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFPyL
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility

    NCT03486886 · start 2017-10-02

    Registered record
    Registry ID
    NCT03486886
    Conditions
    Prostate Cancer
    Interventions
    PSMA -PET/CT scanning
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-10-02
    Completion
    2018-04-30
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPSMA -PET/CT scanning
    PhaseNot applicable
    Registry statusCompleted

  • 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

    NCT03181867 · start 2017-08-03

    Registered record
    Registry ID
    NCT03181867
    Conditions
    Prostate Neoplasms; Prostatic Cancer; Prostate Cancer; Cancer Of Prostate; Metastatic Prostate Cancer
    Interventions
    18F-DCFPyL; 18F-FDG; PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-08-03
    Completion
    2031-02-01
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Neoplasms; Prostatic Cancer; Prostate Cancer; Cancer Of Prostate +1 more
    Intervention18F-DCFPyL; 18F-FDG; PSMA-11
    PhasePhase 2
    Registry statusActive not recruiting

  • 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

    NCT03173924 · start 2017-06-06

    Registered record
    Registry ID
    NCT03173924
    Conditions
    Metastatic Prostate Cancer; Prostatic Neoplasms; Prostate Cancer; Prostatic Cancer; Prostate Neoplasms
    Interventions
    18F-NaF; 18F-DCFPyL; 18F-FDG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-06-06
    Completion
    2028-02-06
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer; Prostatic Neoplasms; Prostate Cancer; Prostatic Cancer +1 more
    Intervention18F-NaF; 18F-DCFPyL; 18F-FDG
    PhasePhase 2
    Registry statusActive not recruiting

  • PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

    NCT03232164 · start 2017-02-02

    Registered record
    Registry ID
    NCT03232164
    Conditions
    Prostate Cancer; Prostate Neoplasm
    Interventions
    18F-DCFPyL PET
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-02-02
    Completion
    2024-11-01
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Prostate Neoplasm
    Intervention18F-DCFPyL PET
    PhaseEarly phase 1
    Registry statusCompleted

  • Advanced Prostate Imaging of Recurrent Cancer After Radiotherapy

    NCT02793284 · start 2017-01-09

    Registered record
    Registry ID
    NCT02793284
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFPyL PET/CT scan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-01-09
    Completion
    2022-02-15
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFPyL PET/CT scan
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

    NCT02856100 · start 2016-08-03

    Registered record
    Registry ID
    NCT02856100
    Conditions
    Prostate Cancer
    Interventions
    18F DCFPyL- Radiopharmaceutical
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-08-03
    Completion
    2020-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F DCFPyL- Radiopharmaceutical
    PhaseNot recorded
    Registry statusCompleted

  • Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer

    NCT02825875 · start 2016-06-08

    Registered record
    Registry ID
    NCT02825875
    Conditions
    Prostate Cancer
    Interventions
    18F DCFPyL- Radiopharmaceutica
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-06-08
    Completion
    2020-04
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F DCFPyL- Radiopharmaceutica
    PhaseNot recorded
    Registry statusCompleted